Anti-CD22 CAR-T Cells

BPS Bioscience

Anti-CD22 CAR-T Cells

23

Other Application

Research Use Only

CD22

CD22 molecule

B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigen; sialic acid-binding Ig-like lectin 2; SIGLEC2; SIGLEC-2; T-cell surface antigen Leu-14

B-cell receptor CD22

The Anti-CD22 CAR-T Cells are produced by high-titer lentiviral transduction of human primary CD4+and CD8+ T cells using the Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3aeta) (#78608). These ready-to-use CAR-T cells express an anti-CD22 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD22(clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3aeta signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. Figure 1. Construct diagram showing components of the anti-CD22 CAR expressed in Anti-CD22 CAR-T Cells.

Liquid Nitrogen

12352203